JPWO2020112880A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020112880A5 JPWO2020112880A5 JP2021530816A JP2021530816A JPWO2020112880A5 JP WO2020112880 A5 JPWO2020112880 A5 JP WO2020112880A5 JP 2021530816 A JP2021530816 A JP 2021530816A JP 2021530816 A JP2021530816 A JP 2021530816A JP WO2020112880 A5 JPWO2020112880 A5 JP WO2020112880A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- individual
- period
- compound
- administering
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 claims description 63
- 229940125904 compound 1 Drugs 0.000 claims description 39
- 150000003839 salts Chemical class 0.000 claims description 28
- 239000012453 solvate Substances 0.000 claims description 28
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 11
- 208000035475 disorder Diseases 0.000 claims description 11
- 230000004044 response Effects 0.000 claims description 11
- 108010074051 C-Reactive Protein Proteins 0.000 claims description 10
- 102100032752 C-reactive protein Human genes 0.000 claims description 10
- 230000002550 fecal effect Effects 0.000 claims description 10
- 102000001109 Leukocyte L1 Antigen Complex Human genes 0.000 claims description 9
- 108010069316 Leukocyte L1 Antigen Complex Proteins 0.000 claims description 9
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 7
- 230000001939 inductive effect Effects 0.000 claims description 6
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 4
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 4
- 239000005557 antagonist Substances 0.000 claims description 4
- 210000004400 mucous membrane Anatomy 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 229960003444 immunosuppressant agent Drugs 0.000 claims description 2
- 239000003018 immunosuppressive agent Substances 0.000 claims description 2
- 102000006495 integrins Human genes 0.000 claims description 2
- 108010044426 integrins Proteins 0.000 claims description 2
- 229960004914 vedolizumab Drugs 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 20
- MVGWUTBTXDYMND-QGZVFWFLSA-N 2-[(3r)-7-[[4-cyclopentyl-3-(trifluoromethyl)phenyl]methoxy]-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl]acetic acid Chemical compound C([C@@H]1CC(=O)O)CC(C2=C3)=C1NC2=CC=C3OCC(C=C1C(F)(F)F)=CC=C1C1CCCC1 MVGWUTBTXDYMND-QGZVFWFLSA-N 0.000 claims 2
- 102100025750 Sphingosine 1-phosphate receptor 1 Human genes 0.000 claims 1
- 101710155454 Sphingosine 1-phosphate receptor 1 Proteins 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000008177 pharmaceutical agent Substances 0.000 claims 1
- DUYSYHSSBDVJSM-KRWOKUGFSA-N sphingosine 1-phosphate Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)COP(O)(O)=O DUYSYHSSBDVJSM-KRWOKUGFSA-N 0.000 description 18
- 102000005962 receptors Human genes 0.000 description 10
- 108020003175 receptors Proteins 0.000 description 10
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 8
- 230000004043 responsiveness Effects 0.000 description 8
- 230000000694 effects Effects 0.000 description 4
- 238000012423 maintenance Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 125000002059 L-arginyl group Chemical class O=C([*])[C@](N([H])[H])([H])C([H])([H])C([H])([H])C([H])([H])N([H])C(=N[H])N([H])[H] 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 238000005259 measurement Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 208000011231 Crohn disease Diseases 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 208000002551 irritable bowel syndrome Diseases 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 230000037221 weight management Effects 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024195531A JP2025024035A (ja) | 2018-11-30 | 2024-11-08 | Ｓ１ｐ１受容体に関連する状態を治療する方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862773936P | 2018-11-30 | 2018-11-30 | |
| US62/773,936 | 2018-11-30 | ||
| US201962850464P | 2019-05-20 | 2019-05-20 | |
| US62/850,464 | 2019-05-20 | ||
| PCT/US2019/063413 WO2020112880A1 (en) | 2018-11-30 | 2019-11-26 | Methods of treating conditions related to the s1p1 receptor |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024195531A Division JP2025024035A (ja) | 2018-11-30 | 2024-11-08 | Ｓ１ｐ１受容体に関連する状態を治療する方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022511788A JP2022511788A (ja) | 2022-02-01 |
| JPWO2020112880A5 true JPWO2020112880A5 (enExample) | 2022-12-05 |
Family
ID=68966033
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021530816A Withdrawn JP2022511788A (ja) | 2018-11-30 | 2019-11-26 | Ｓ１ｐ１受容体に関連する状態を治療する方法 |
| JP2024195531A Pending JP2025024035A (ja) | 2018-11-30 | 2024-11-08 | Ｓ１ｐ１受容体に関連する状態を治療する方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024195531A Pending JP2025024035A (ja) | 2018-11-30 | 2024-11-08 | Ｓ１ｐ１受容体に関連する状態を治療する方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20220023258A1 (enExample) |
| EP (1) | EP3886841A1 (enExample) |
| JP (2) | JP2022511788A (enExample) |
| KR (1) | KR102824401B1 (enExample) |
| CN (2) | CN118649163A (enExample) |
| AU (1) | AU2019387212A1 (enExample) |
| CA (1) | CA3120706A1 (enExample) |
| IL (1) | IL283414A (enExample) |
| WO (1) | WO2020112880A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10201500639TA (en) | 2010-01-27 | 2015-03-30 | Arena Pharm Inc | Processes for the preparation of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof |
| ES2995737T3 (en) | 2015-01-06 | 2025-02-11 | Arena Pharm Inc | Compound for use in treating conditions related to the s1p1 receptor |
| MA42807A (fr) | 2015-06-22 | 2018-07-25 | Arena Pharm Inc | Sel l-arginine cristallin d'acide (r)-2-(7-(4-cyclopentyl-3-(trifluorométhyl)benzyloxy)-1,2,3,4-tétrahydrocyclo-penta[b]indol-3-yl)acétique (composé 1) pour une utilisation dans des troubles associés au récepteur de s1p1 |
| WO2018151873A1 (en) | 2017-02-16 | 2018-08-23 | Arena Pharmaceuticals, Inc. | Compounds and methods for treatment of primary biliary cholangitis |
| CA3053416A1 (en) | 2017-02-16 | 2018-08-23 | Arena Pharmaceuticals, Inc. | Compounds and methods for treatment of inflammatory bowel disease with extra-intestinal manifestations |
| EP3801459B1 (en) | 2018-06-06 | 2024-08-07 | Arena Pharmaceuticals, Inc. | Methods of treating conditions related to the s1p1 receptor |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104311472B9 (zh) | 2008-07-23 | 2020-03-17 | 艾尼纳制药公司 | 经取代的1,2,3,4-四氢环戊并[b]吲哚-3-基乙酸衍生物 |
| SG10201500639TA (en) | 2010-01-27 | 2015-03-30 | Arena Pharm Inc | Processes for the preparation of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof |
| JP2015505564A (ja) * | 2012-02-03 | 2015-02-23 | テバ ファーマシューティカル インダストリーズ リミティド | 第一選択の抗ＴＮＥα療法に失敗したクローン病患者を治療するためのラキニモドの使用 |
| KR20170005058A (ko) * | 2014-05-09 | 2017-01-11 | 노그라 파마 리미티드 | 염증성 장 질환을 치료하는 방법 |
| ES2995737T3 (en) * | 2015-01-06 | 2025-02-11 | Arena Pharm Inc | Compound for use in treating conditions related to the s1p1 receptor |
| JP2018531936A (ja) * | 2015-09-30 | 2018-11-01 | ノグラ ファーマ リミテッド | バイオマーカー発現に基づいてｓｍａｄ７アンチセンスオリゴヌクレオチドを使用する方法 |
| WO2018151873A1 (en) * | 2017-02-16 | 2018-08-23 | Arena Pharmaceuticals, Inc. | Compounds and methods for treatment of primary biliary cholangitis |
-
2019
- 2019-11-26 KR KR1020217019803A patent/KR102824401B1/ko active Active
- 2019-11-26 CN CN202410692934.XA patent/CN118649163A/zh active Pending
- 2019-11-26 US US17/299,741 patent/US20220023258A1/en not_active Abandoned
- 2019-11-26 CN CN201980087042.4A patent/CN113226307A/zh active Pending
- 2019-11-26 AU AU2019387212A patent/AU2019387212A1/en not_active Abandoned
- 2019-11-26 JP JP2021530816A patent/JP2022511788A/ja not_active Withdrawn
- 2019-11-26 EP EP19824097.0A patent/EP3886841A1/en active Pending
- 2019-11-26 CA CA3120706A patent/CA3120706A1/en active Pending
- 2019-11-26 WO PCT/US2019/063413 patent/WO2020112880A1/en not_active Ceased
-
2021
- 2021-05-25 IL IL283414A patent/IL283414A/en unknown
-
2024
- 2024-11-08 JP JP2024195531A patent/JP2025024035A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4938905B2 (ja) | 選択的ｓ１ｐ１レセプターアゴニストの投与法 | |
| US20200323843A1 (en) | Use of levocetirizine and montelukast in the treatment of viral infection caused by coronavirus | |
| JP2015526458A5 (enExample) | ||
| WO2010071866A2 (en) | Combination therapy for arthritis with tranilast | |
| JP5362151B2 (ja) | Ｐｇｄ２拮抗剤及びヒスタミン拮抗剤からなるアレルギー性鼻炎治療用医薬 | |
| JP2017119702A (ja) | ギラン・バレー症候群に伴う神経因性疼痛の予防又は治療剤 | |
| JPWO2020112880A5 (enExample) | ||
| TWI777059B (zh) | 肌肉減少症之預防劑及治療劑 | |
| CN115702143A (zh) | 治疗系统性硬化症的方法 | |
| JPWO2020146529A5 (enExample) | ||
| JP2002523363A (ja) | 慢性疲労症候群および／または線維筋痛の処置のためのサブスタンスｐアンタゴニストの使用および慢性疲労症候群の処置のためのｎｋ−１レセプターアンタゴニストの使用 | |
| US11666587B2 (en) | Veterinary composition comprising torasemide for the treatment of pulmonary edema associated with heart failure in domestic animals | |
| JP2009535336A (ja) | 片頭痛治療用の固定組合せ剤形 | |
| JP2024518426A (ja) | 投与レジメン | |
| JPWO2020072824A5 (enExample) | ||
| WO2016006621A1 (ja) | Ｐｇｄ２拮抗剤を含有するアレルギー性疾患に伴う症状の治療用医薬 | |
| JPWO2021142030A5 (enExample) | ||
| US12048677B2 (en) | Compositions and uses thereof for the treatment of heart failure in domestic animals | |
| RU2021123406A (ru) | Способы лечения состояний, связанных с рецептором s1p1 | |
| HUP0401696A2 (hu) | Angiotenzin-II receptor antagonistát tartalmazó gyógyászati készítmény | |
| JPWO2021067506A5 (enExample) | ||
| JP2000355551A (ja) | 医薬組成物 | |
| TW200906406A (en) | Use of a compound that is a neurokinin A NK2 receptor antagonist for the preparation of medicaments for use in the prevention and treatment of sexual dysfunctions | |
| WO2023236781A1 (zh) | 治疗精神类疾病的方法 | |
| JPWO2022101395A5 (enExample) |